{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:21:37Z","timestamp":1781263297121,"version":"3.54.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"DHHS\/NIH\/NCI Spore"}],"content-domain":{"domain":["thegreenjournal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.radonc.2018.11.002","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T19:02:26Z","timestamp":1545332546000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-0473","authenticated-orcid":false,"given":"Chi","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5863-6023","authenticated-orcid":false,"given":"Vivek","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan P.","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Lazenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Sasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrakanth","family":"Are","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L.","family":"Grem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2018.11.002_b0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/COC.0000000000000278","article-title":"Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications","volume":"39","author":"Verma","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000267","article-title":"Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages","volume":"7","author":"Gillen","year":"2010","journal-title":"PLoS Med"},{"key":"10.1016\/j.radonc.2018.11.002_b0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.soc.2004.06.007","article-title":"Neoadjuvant therapy for resectable pancreatic cancer","volume":"13","author":"Raut","year":"2004","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.radonc.2018.11.002_b0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1634\/theoncologist.7-1-34","article-title":"Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation","volume":"7","author":"Wayne","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2018.11.002_b0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S1091-255X(00)80105-5","article-title":"Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators","volume":"4","author":"Sohn","year":"2000","journal-title":"J Gastroenterol Surg"},{"key":"10.1016\/j.radonc.2018.11.002_b0030","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1634\/theoncologist.2011-0268","article-title":"Neoadjuvant therapy of pancreatic cancer: the emerging paradigm?","volume":"17","author":"Lim","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.radonc.2018.11.002_b0035","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.radonc.2016.12.030","article-title":"Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial","volume":"122","author":"Verma","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0040","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13014-017-0798-8","article-title":"Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial","volume":"12","author":"Verma","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/cncr.26365","article-title":"Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer","volume":"118","author":"Murphy","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2016.10.030","article-title":"Stereotactic body radiation therapy for locally advanced pancreatic cancer: a systematic review and pooled analysis of 19 trials","volume":"97","author":"Petrelli","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0055","doi-asserted-by":"crossref","first-page":"49530","DOI":"10.1074\/jbc.M306782200","article-title":"Isoform-specific regulation of insulin-dependent glucose uptake by Akt\/protein kinase B","volume":"278","author":"Bae","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.radonc.2018.11.002_b0060","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1158\/0008-5472.CAN-05-1220","article-title":"HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo","volume":"65","author":"Gupta","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2018.11.002_b0065","doi-asserted-by":"crossref","first-page":"9252","DOI":"10.1158\/0008-5472.CAN-06-1239","article-title":"Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.radonc.2018.11.002_b0070","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.radonc.2016.03.024","article-title":"The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells","volume":"119","author":"Al-Assar","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0075","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/00002030-200110190-00009","article-title":"Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)","volume":"15","author":"Saag","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.radonc.2018.11.002_b0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JTO.0b013e3182435aa6","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir with concurrent chemoradiotherapy (CT-RT) for unresectable stage IIIA\/IIIB NSCLC: a report of toxicities and clinical response","volume":"7","author":"Rengan","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.radonc.2013.03.023","article-title":"Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer","volume":"107","author":"Buijsen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-013-1303-3","article-title":"A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme","volume":"116","author":"Alonso-Basanta","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0095","doi-asserted-by":"crossref","first-page":"8161","DOI":"10.18632\/oncotarget.2415","article-title":"A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors","volume":"5","author":"Blumenthal","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2018.11.002_b0100","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hed.23664","article-title":"Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: results of a phase II clinical trial","volume":"37","author":"Hoover","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.radonc.2018.11.002_b0105","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1158\/1078-0432.CCR-15-1489","article-title":"Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer","volume":"22","author":"Hill","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2018.11.002_b0110","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2007.15.2355","article-title":"Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer","volume":"26","author":"Brunner","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.radonc.2016.03.021","article-title":"ARCII: a phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer","volume":"119","author":"Wilson","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0120","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1002\/cncr.30706","article-title":"Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation","volume":"123","author":"Zhong","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0125","unstructured":"National Comprehensive Cancer Network. Pancreatic adenocarcinoma. Version 3.2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf Accessed March 27, 2018."},{"key":"10.1016\/j.radonc.2018.11.002_b0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bcp.12620","article-title":"Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer","volume":"80","author":"Kattel","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.radonc.2018.11.002_b0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/cncr.24059","article-title":"Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas","volume":"115","author":"Chang","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.prro.2013.06.004","article-title":"Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus","volume":"4","author":"Jabbour","year":"2014","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0145","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ijrobp.2003.11.004","article-title":"Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer","volume":"58","author":"Koong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0150","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well-tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0155","doi-asserted-by":"crossref","first-page":"8156","DOI":"10.3748\/wjg.v21.i26.8156","article-title":"Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer","volume":"21","author":"Su","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.radonc.2018.11.002_b0160","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0170","unstructured":"Radiation Therapy Oncology Group. RTOG 0631 Protocol Information. https:\/\/www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=0631 Accessed January 28, 2018."},{"key":"10.1016\/j.radonc.2018.11.002_b0175","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-003-0698-5","article-title":"Phase I trial of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin in adult cancer patients","volume":"53","author":"Grem","year":"2003","journal-title":"Cancer Chemoth and Pharmacol"},{"key":"10.1016\/j.radonc.2018.11.002_b0180","doi-asserted-by":"crossref","first-page":"i53","DOI":"10.1093\/jrr\/rrw016","article-title":"Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer","volume":"57","author":"Crane","year":"2016","journal-title":"J Radiat Res"},{"key":"10.1016\/j.radonc.2018.11.002_b0185","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0190","unstructured":"Clinicaltrials.gov. Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer (SBRT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02454140 Accessed January 28, 2018."},{"key":"10.1016\/j.radonc.2018.11.002_b0195","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijrobp.2017.05.034","article-title":"SBRT for unresectable pancreatic cancer can improve local control with minimal toxicity","volume":"99","author":"Ng","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0205","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/1097-0142(197506)35:6<1678::AID-CNCR2820350629>3.0.CO;2-K","article-title":"Modification of radiation injury to normal tissue by chemotherapeutic agents","volume":"35","author":"Phillips","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/thx.42.1.77","article-title":"Massive haemoptysis as a late consequence of pulmonary irradiation","volume":"42","author":"Isaacs","year":"1987","journal-title":"Thorax"},{"key":"10.1016\/j.radonc.2018.11.002_b0215","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-8140(98)00103-0","article-title":"Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial bracytherapy really a risk factor?","volume":"49","author":"Langendijk","year":"1998","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0220","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1212\/01.wnl.0000257095.33125.48","article-title":"Moyamoya following cranial irradiation for primary brain tumors in children","volume":"68","author":"Ullrich","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.radonc.2018.11.002_b0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00066-010-2114-5","article-title":"Acute arterial hemorrhage following radiotherapy of oropharyngeal squamous cell carcinoma","volume":"186","author":"Greve","year":"2010","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2018.11.002_b0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11604-010-0503-4","article-title":"Carotid blowout syndrome with oronasal hemorrhage: magnetic resonance imaging findings","volume":"29","author":"Yanik","year":"2011","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.radonc.2018.11.002_b0235","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2407-12-27","article-title":"Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy","volume":"12","author":"Ito","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2018.11.002_b0240","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jamaoto.2013.103","article-title":"Risk factors for hemorrhage after chemoradiation for oropharyngeal squamous cell carcinoma","volume":"139","author":"Self","year":"2013","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.radonc.2018.11.002_b0245","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11060-015-1839-5","article-title":"Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors","volume":"124","author":"Aizer","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2018.11.002_b0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijrobp.2016.10.015","article-title":"Cerebrovascular diseases in childhood cancer survivors: role of the radiation dose to Willis circle arteries","volume":"97","author":"El-Fayech","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2018.11.002_b0255","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/0883073818756729","article-title":"Large vessel arteriopathy after cranial radiation therapy in pediatric brain tumor survivors","volume":"33","author":"Nordstrom","year":"2018","journal-title":"J Child Neurol"},{"key":"10.1016\/j.radonc.2018.11.002_b0260","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13014-015-0489-2","article-title":"Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas","volume":"10","author":"Elhammali","year":"2015","journal-title":"Radiat Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018335837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814018335837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,2]],"date-time":"2019-03-02T08:48:26Z","timestamp":1551516506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814018335837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":52,"alternative-id":["S0167814018335837"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2018.11.002","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2018.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}